FORCYL DIN 02474441
Health Canada record
| Active ingredient(s) | MARBOFLOXACIN 160 MG |
|---|---|
| Dosage form | Solution |
| Route | Intramuscular |
| Schedule | PRESCRIPTION |
| Class | Veterinary |
| ATC | |
| Original market date | 21-Mar-2019 |
| Current status date | 21-Mar-2019 |
| Source | Health Canada DPD |
Establishment licence of the holder
Vetoquinol N A Inc. — licence 100448, currently licensed, last inspection rating C (2025-10-20).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing MARBOFLOXACIN
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02353970 | AURIZON | VETOQUINOL N A INC | Suspension | MARBOFLOXACIN 3 MG; CLOTRIMAZOLE 10 MG; DEXAMETHASONE (DEXAMETHASONE ACETATE) 0.9 MG | Marketed |
| 02241414 | ZENIQUIN | ZOETIS CANADA INC | Tablet | MARBOFLOXACIN 50 MG | Marketed |
| 02241415 | ZENIQUIN | ZOETIS CANADA INC | Tablet | MARBOFLOXACIN 25 MG | Marketed |
| 02241412 | ZENIQUIN | ZOETIS CANADA INC | Tablet | MARBOFLOXACIN 200 MG | Marketed |
| 02241413 | ZENIQUIN | ZOETIS CANADA INC | Tablet | MARBOFLOXACIN 100 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 20700 | 2018-04-06 | New Drug Submission (NDS) |
International API supply for MARBOFLOXACIN
2 active FDA Drug Master Files.
Request a quote for FORCYL